Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer

Published:2024-09-05 Issue: Volume: Page:
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Thorat Mangesh A.¹²,Cuzick Jack²,Chan Andrew T.³

Affiliation:

1. Breast Service, Homerton University Hospital, London, United Kingdom

2. Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom

3. Massachusetts General Hospital and Harvard Medical School, Harvard T.H. Chan School of Public Health, Boston

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jama/articlepdf/2823276/jama_thorat_2024_le_240106_1724966726.74442.pdf

Reference5 articles.

1. Aspirin vs placebo as adjuvant therapy for breast cancer: the Alliance A011502 randomized trial.;Chen;JAMA,2024

2. ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.;Coyle;Contemp Clin Trials,2016

3. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.;Rothwell;Lancet,2012

4. Aspirin in the prevention of colorectal neoplasia.;Drew;Annu Rev Med,2021

5. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years.;Pan;N Engl J Med,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP